title: Pilot study on the use of sublingual misoprostol with mifepristone in termination of first trimester pregnancy up to 9 weeks gestation.
abstract: BACKGROUND
  A combination of mifepristone and misoprostol provides an effective method of medical abortion for early pregnancy. A new route of administration of misoprostol, the sublingual route, was investigated in this study.
  
  
  METHODS
  One hundred women who requested legal termination of pregnancy up to 63 days were given 200 mg of oral mifepristone followed 48 h later by 800 microg (4 x 200 microg tablets) of sublingual misoprostol.
  
  
  RESULTS
  Ninety-four women (94%) had a complete abortion with this regimen. There was one ongoing pregnancy. The median duration of vaginal bleeding was 15 days. There were no serious complications. However, lower abdominal pain, diarrhoea, chills and fever were the commonest side-effects with incidences of 89, 42, 38 and 79% respectively.
  
  
  CONCLUSIONS
  The combination of mifepristone and sublingual misoprostol is effective for medical abortion up to 63 days gestation. Randomized trials are required to compare its efficacy and side-effect profile with vaginal misoprostol.
authors.affiliation: Department of Obstetrics and Gynaecology, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Rd, Hong Kong SAR, People's Republic of China. ostang@graduate.hku.hk
authors.forename: Oi Shan
authors.initials: OS
authors.lastname: Tang
authors.forename: Jieshuang
authors.initials: J
authors.lastname: Xu
authors.forename: Linan
authors.initials: L
authors.lastname: Cheng
authors.forename: Sharon W H
authors.initials: SW
authors.lastname: Lee
authors.forename: Pak Chung
authors.initials: PC
authors.lastname: Ho
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D000021:Abortifacient Agents, Steroidal / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D000028:Abortion, Induced / Q000379:methods*; D000284:Administration, Oral; D000286:Administration, Sublingual; D000328:Adult; D004357:Drug Synergism; D005260:Female; D005865:Gestational Age; D006801:Humans; D015735:Mifepristone / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D016595:Misoprostol / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D010865:Pilot Projects; D011247:Pregnancy; D011261:Pregnancy Trimester, First
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D000021:Abortifacient Agents, Steroidal; D016595:Misoprostol; D015735:Mifepristone